Canadian health authorities approved Amylix Pharmaceuticals Inc.’s new drug for amyotrophic lateral sclerosis, the progressive neurodegenerative disease that robs patients of their ability to walk and speak.
This is Canada’s first approval since 2018 for a new drug to treat the fatal condition, also known as Lou Gehrig’s disease,